TRX-103 is under development for the treatment of graft versus host disease (GvHD), Crohn’s disease and unspecified indication. The therapeutic candidate comprises of allogenic Treg-cells which are ...

AbGn-168H is under clinical development by AltruBio and currently in Phase I for Graft Versus Host Disease (GVHD).

Mesoblast stock climbs 80% in a month following the FDA's approval of Ryoncil as the only approved therapy for SR-aGVHD in children aged two months and older.

The FDA approved several drugs in December for the treatment of diseases including pancreatic adenocarcinoma, lung cancer, ...

Mesoblast's FDA approval for remestemcel marks a milestone for MSC therapies, but limited cash reserves pose risks for US ...

The therapy – which is a standardised preparation of faecal bacterial species from donors – showed “a clear reduction in disease burden ... with acute graft-versus-host disease (aGvHD ...

Kadmon claimed approval for Rezurock (belumosudil) in July as a treatment for chronic graft versus host disease (GVHD) – a common and often fatal complication that can follow a bone marrow ...

China's top drug regulator has recently approved the nation's first stem cell therapy to treat a type of complication associated with bone marrow transplant, as well as a novel HIV drug that only ...

Patients can die if they take certain previously prescribed beta-blockers during a hematopoietic cell transplant due to ...

fantasy cricket expert Strategies for the development of new drugs for graft-versus-host disease (GVHD) $100 million! Hausen Pharmaceuticals licenses EQRx to acquire rights to Ametinib outside China ...

In an interview with Peers & Perspectives in Oncology, Doris M. Ponce, MD, MS, a bone marrow transplant specialist, discussed how telehealth made a significant impact on patients with rare diseases ...

JAKARTA: Indonesian President Prabowo Subianto has doubled down on his stance against those convicted of graft, days after making an apparent U-turn on an earlier statement suggesting his ...